Abnormalities in GLS are associated with mortality and waitlist decompensation signaling GLS as another marker for adverse clinical outcomes
A few key players are AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical
Tiered Impact on Indian Equities The market impact is not uniform
Techniques likely employed included: Power calculations to determine optimal sample sizes Bayesian adaptive trial design for dose optimization Pharmacokinetic/pharmacodynamic (PK/PD) modeling to predict clinical responses Time-series analysis of metabolic parameters Multivariate analysis to account for confounding variables Predictive analytics for patient dropout and adherence These computational approaches ensured efficient use of resources while maintaining statistical rigor in evaluating orforgliprons safety and efficacy
Common adverse reactions include gastrointestinal symptoms (which may lead to intestinal obstruction in severe cases), headache, migraine, dehydration, and erectile dysfunction
